CYP2A7

Cytochrome P450, family 2, subfamily A, polypeptide 7
Identifiers
Symbols	CYP2A7 ; CPA7; CPAD; CYP2A; CYPIIA7; P450-IIA4
External IDs	OMIM: 608054 HomoloGene: 85917 IUPHAR: 1322 GeneCards: CYP2A7 Gene
EC number	1.14.14.1
Gene ontology Molecular function • iron ion binding • arachidonic acid epoxygenase activity • steroid hydroxylase activity • oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen • oxygen binding • heme binding • aromatase activity Cellular component • cytoplasm • endoplasmic reticulum membrane • intracellular membrane-bounded organelle Biological process • xenobiotic metabolic process • coumarin metabolic process • epoxygenase P450 pathway • exogenous drug catabolic process • oxidation-reduction process Sources: Amigo / QuickGO
Orthologs
Species	Human	Mouse
Entrez	1549	13086
Ensembl	ENSG00000198077	ENSMUSG00000074254
UniProt	P20853	P15392
RefSeq (mRNA)	NM_000764	NM_009997
RefSeq (protein)	NP_000755	NP_034127
Location (UCSC)	Chr 19: 40.88 – 40.88 Mb	Chr 7: 26.31 – 26.32 Mb
PubMed search

CYP2A7 (cytochrome P450, family 2, subfamily A, polypeptide 7) is a protein that in humans is encoded by the CYP2A7 gene.^[1][2]

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum; its substrate has not yet been determined. This gene, which produces two transcript variants, is part of a large cluster of cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q.^[3]

References

1. Fernandez-Salguero P, Hoffman SM, Cholerton S, Mohrenweiser H, Raunio H, Rautio A, Pelkonen O, Huang JD, Evans WE, Idle JR (September 1995). "A Genetic Polymorphism in Coumarin 7-Hydroxylation: Sequence of the Human CYP2A Gnes and Identification of Variant CYP2A6 Alleles". Am. J. Hum. Genet. 57 (3): 651–60. PMC: 1801261. PMID 7668294.
2. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW (January 2004). "Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants". Pharmacogenetics 14 (1): 1–18. doi:10.1097/00008571-200401000-00001. PMID 15128046.
3. "Entrez Gene: CYP2A7".

Further reading

• Smith BD, Sanders JL, Porubsky PR; et al. (2007). "Structure of the human lung cytochrome P450 2A13". J. Biol. Chem. 282 (23): 17306–13. doi:10.1074/jbc.M702361200. PMID 17428784.
• Wang HH, Liao YW, Chiang HL; et al. (2009). "Novel DNA sequence variations of cytochrome P450 genes in the Han Chinese population". Pharmacogenomics 10 (3): 359–74. doi:10.2217/14622416.10.3.359. PMID 19290787.
• Fernandez-Salguero P, Gonzalez FJ (1995). "The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis". Pharmacogenetics 5 (Special Issue): S123–8. doi:10.1097/00008571-199512001-00013. PMID 7581481.
• Cauffiez C, Lo-Guidice JM, Quaranta S; et al. (2004). "Genetic polymorphism of the human cytochrome CYP2A13 in a French population: implication in lung cancer susceptibility". Biochem. Biophys. Res. Commun. 317 (2): 662–9. doi:10.1016/j.bbrc.2004.03.092. PMID 15063809.
• Timofeeva MN, Kropp S, Sauter W; et al. (2009). "CYP450 polymorphisms as risk factors for early-onset lung cancer: gender-specific differences". Carcinogenesis 30 (7): 1161–9. doi:10.1093/carcin/bgp102. PMID 19414505.
• Smith G, Stubbins MJ, Harries LW, Wolf CR (1998). "Molecular genetics of the human cytochrome P450 monooxygenase superfamily". Xenobiotica 28 (12): 1129–65. doi:10.1080/004982598238868. PMID 9890157.
• Saito A, Kawamoto M, Kamatani N (2009). "Association study between single-nucleotide polymorphisms in 199 drug-related genes and commonly measured quantitative traits of 752 healthy Japanese subjects". J. Hum. Genet. 54 (6): 317–23. doi:10.1038/jhg.2009.31. PMID 19343046.
• He XY, Shen J, Ding X; et al. (2004). "Identification of critical amino acid residues of human CYP2A13 for the metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific carcinogen". Drug Metab. Dispos. 32 (12): 1516–21. doi:10.1124/dmd.104.001370. PMID 15333516.
• Nelson DR, Zeldin DC, Hoffman SM; et al. (2004). "Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants". Pharmacogenetics 14 (1): 1–18. doi:10.1097/00008571-200401000-00001. PMID 15128046.
• He XY, Shen J, Hu WY; et al. (2004). "Identification of Val117 and Arg372 as critical amino acid residues for the activity difference between human CYP2A6 and CYP2A13 in coumarin 7-hydroxylation". Arch. Biochem. Biophys. 427 (2): 143–53. doi:10.1016/j.abb.2004.03.016. PMID 15196988.
• Herr D, Bettendorf H, Denschlag D; et al. (2006). "Cytochrome P2A13 and P1A1 gene polymorphisms are associated with the occurrence of uterine leiomyoma". Arch. Gynecol. Obstet. 274 (6): 367–71. doi:10.1007/s00404-006-0201-8. PMID 16835796.
• Song DK, Xing DL, Zhang LR; et al. (2009). "Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China". Cancer Detect. Prev. 32 (5–6): 416–23. doi:10.1016/j.cdp.2009.02.003. PMID 19303722.
• Fujieda M, Yamazaki H, Kiyotani K; et al. (2003). "Eighteen novel polymorphisms of the CYP2A13 gene in Japanese". Drug Metab. Pharmacokinet. 18 (1): 86–90. doi:10.2133/dmpk.18.86. PMID 15618722.
• Wang H, Tan W, Hao B; et al. (2003). "Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK". Cancer Res. 63 (22): 8057–61. PMID 14633739.
• Cheng XY, Chen GL, Zhang WX; et al. (2004). "Arg257Cys polymorphism of CYP2A13 in a Chinese population". Clin. Chim. Acta 343 (1–2): 213–6. doi:10.1016/j.cccn.2004.01.017. PMID 15115698.
• D'Agostino J, Zhang X, Wu H; et al. (2008). "Characterization of CYP2A13*2, a variant cytochrome P450 allele previously found to be associated with decreased incidences of lung adenocarcinoma in smokers". Drug Metab. Dispos. 36 (11): 2316–23. doi:10.1124/dmd.108.022822. PMC: 2597635. PMID 18669584.
• Cauffiez C, Pottier N, Tournel G; et al. (2005). "CYP2A13 genetic polymorphism in French Caucasian, Gabonese and Tunisian populations". Xenobiotica 35 (7): 661–9. doi:10.1080/00498250500202171. PMID 16316926.
• Mohelnikova-Duchonova B, Vrana D, Holcatova I; et al. (2010). "CYP2A13, ADH1B, and ADH1C gene polymorphisms and pancreatic cancer risk". Pancreas 39 (2): 144–8. doi:10.1097/MPA.0b013e3181bab6c2. PMID 19812523.
• Jiang JH, Jia WH, Chen HK; et al. (2004). "Genetic polymorphisms of CYP2A13 and its relationship to nasopharyngeal carcinoma in the Cantonese population". J Transl Med 2 (1): 24. doi:10.1186/1479-5876-2-24. PMC: 455696. PMID 15222883.
• Young RP, Hopkins RJ, Hay BA; et al. (2009). "A gene-based risk score for lung cancer susceptibility in smokers and ex-smokers". Postgrad Med J 85 (1008): 515–24. doi:10.1136/pgmj.2008.077107. PMID 19789190.

This article incorporates text from the United States National Library of Medicine, which is in the public domain.